Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Asciminib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Survey Administration; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Bladder Cancer
Interventions: Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 14 more

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-210, Mitomycin C, Gemcitabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 27
States / cities: Sun City, Arizona • Los Angeles, California • Lakewood, Colorado + 23 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced-stage Solid Tumors
Interventions: JNJ-89862175; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Orlando, Florida • Boston, Massachusetts • Irving, Texas

Conditions: Spondylolisthesis, Spinal Stenosis, Degenerative Disease
Interventions: Prospective follow-up of patients who have received instrumented lumbar arthrodesis supplemented the Implanet Jazz System(TM); Other
Lead sponsor: Francis Farhadi; Other
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: UroAmp Test (Convergent Genomics, Inc.); Diagnostic Test
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Generalized Anxiety Disorder
Interventions: ITI-1284; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Brooklyn, New York

Conditions: Athletes in Cutting Sports
Interventions: Ankle tape, Standard lace-up ankle brace, Standard high ankle-sprain (HAS) brace, Low-profile HAS brace, No ankle brace or tape; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Mantle Cell Lymphoma
Interventions: Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Glofitamab, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography; Drug · Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Graves' Disease, Graves Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Biological · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 29
States / cities: Carlsbad, California • Orange, California • Pasadena, California + 24 more

Conditions: Asthma
Interventions: JNJ-95597528, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Westminster, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Recruiting clinical trials

Filter and sort this status page

Live official records

Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Spironolactone for Pulmonary Arterial Hypertension

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Thoracic-Lumbar Arthrodesis- Implanet Jazz

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)

Enovis High Ankle Sprain Brace Testing

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma